Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of targets of clinical FOXA1 mutants involved in EMT and immune suppression in prostate cancer.

Communications biology·2026
Same author

RNAs anchoring replication complex control initiation and firing of DNA replication.

Nature communications·2026
Same author

Immune Spatial Organization Predicts Distant Metastasis Risk in Aggressive Localized Prostate Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancer.

Signal transduction and targeted therapy·2026
Same author

FOXJ1 mediates taxane resistance through regulation of microtubule dynamics.

Nature communications·2026
Same author

Lack of synergy between AR-targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancer.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same journal

Editor's Note: Akt/mTOR Counteract the Antitumor Activities of Cixutumumab, an Anti-Insulin-like Growth Factor I Receptor Monoclonal Antibody.

Molecular cancer therapeutics·2026
Same journal

Preclinical Comparison of Two CD3xB7H4 Bispecific Antibodies for Solid Tumor Therapy Reveals CD3 Affinity-Dependent Potency and Tolerability Tradeoffs.

Molecular cancer therapeutics·2026
Same journal

RIG-I-targeted immunotherapy synergizes with immune checkpoint inhibition in a hepatocellular carcinoma model.

Molecular cancer therapeutics·2026
Same journal

Improving Immune Checkpoint Blockade Efficacy in Melanoma Brain Metastases through Myddosomal inhibition with Emavusertib.

Molecular cancer therapeutics·2026
Same journal

Anti-Tumor Activity of Cdk2/9 Inhibitor Fadraciclib in an In Vivo Model of Temozolomide Refractory Neuroblastoma.

Molecular cancer therapeutics·2026
Same journal

Concurrent inhibition of ICMT and RAF/MEK suppresses RAC1P29S-driven MAPK-pathway-inhibitor resistance in BRAFV600E melanoma by regulating TAZ activity.

Molecular cancer therapeutics·2026
See all related articles

Related Experiment Video

Updated: May 21, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

12.9K

Heterogeneous Responses to High-Dose Testosterone in Castration-Resistant Prostate Cancer Tumors with Mixed

Maryam Labaf1,2,3, Wanting Han1,4,5, Songqi Zhang1,4

  • 1Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts.

Molecular Cancer Therapeutics
|March 21, 2025
PubMed
Summary
This summary is machine-generated.

High-dose testosterone (Hi-T) effectively treats castration-resistant prostate cancer (CRPC) in Rb-proficient cells. Rb-deficient CRPC cells resist Hi-T, but hypoxia inhibition can restore sensitivity.

More Related Videos

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses
08:36

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Published on: October 24, 2019

11.0K
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.2K

Related Experiment Videos

Last Updated: May 21, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

12.9K
Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses
08:36

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Published on: October 24, 2019

11.0K
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.2K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Androgen deprivation therapy is standard for prostate cancer, but resistance leads to aggressive castration-resistant prostate cancer (CRPC).
  • Current treatments for CRPC, including enzalutamide and abiraterone, offer only transient benefits.
  • High-dose testosterone (Hi-T) shows promise for CRPC by suppressing E2F and MYC signaling, but the role of Rb family proteins is unclear.

Purpose of the Study:

  • To investigate the role of Rb family proteins in CRPC response to Hi-T.
  • To identify mechanisms of resistance to Hi-T in CRPC.
  • To explore strategies for overcoming Hi-T resistance in CRPC.

Main Methods:

  • Utilized a CRPC patient-derived xenograft model with Rb-proficient and Rb-deficient cell populations.
  • Performed single-cell RNA sequencing to analyze cellular responses to Hi-T.
  • Investigated the effect of hypoxia-inducible factor-1α (HIF-1α) inhibition in RB1-silenced CRPC cell lines.

Main Results:

  • Rb-proficient CRPC cells showed a strong response to Hi-T, while Rb-deficient cells exhibited significant resistance.
  • Rb-deficient CRPC cells displayed an enriched hypoxia signature.
  • Inhibition of HIF-1α restored sensitivity of Rb-deficient CRPC cells to high-dose dihydrotestosterone (Hi-DHT).

Conclusions:

  • Rb family protein status significantly influences CRPC response to Hi-T.
  • Hypoxia signaling is implicated in Hi-T resistance in Rb-deficient CRPC.
  • Targeting hypoxia offers a potential strategy to resensitize Rb-deficient CRPC to Hi-T treatment.